Diabetes care in the US and Canada

被引:8
作者
Booth, GL
Zinman, B
Redelmeier, DA
机构
[1] St Michaels Hosp, Div Endocrinol & Metab, Dept Med, Toronto, ON M5C 2T2, Canada
[2] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada
[3] Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON, Canada
关键词
D O I
10.2337/diacare.25.7.1149
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE - To compare the glycemic control of patients with type I diabetes treated in the U.S. and Canada. RESEARCH DESIGN AND METHODS - A large multicenter randomized clinical trial conducted in the U.S. and Canada was analyzed. Patients With type I diabetes, screened from 1983 to 1989 For enrollment in the Diabetes Control and Complications Trial (DCCT), were categorized as treated in the U.S. (n = 204) or Canada (n = 245). HbA(1c) levels were compared between U.S. and Canadian patients, both before and after adjustment for predictors of HbA(1c). RESULTS - in general, volunteers screened for the DCCT were highly educated and following healthy lifestyles. Canadians were somewhat younger (25 vs. 27 years of age, P = 0.002) less likely to be college educated (62 vs. 71%, P = 0.002), more likely to receive care through a family doctor (41 vs. 28%, P = 0.001), and had a higher frequency of out-patient visits (4 vs. 3 per year, P = 0.004). Despite these differences in health care delivery, the mean HbA(1c) at baseline was identical in the two countries (8.9 vs 9.0, P = 0.40). Adjustment for demographic, lifestyle, and clinical predictors of HbA(1c) yielded similar findings (9.0 vs. 9.2, P = 0.15). Equal percentages of American and Canadian patients who were screened ultimately entered the trial (21 vs. 19%, P = 0.20), and those randomized to conventional care achieved similar mean HbA(1c) levels (9.1 vs. 9.2, P = 0.50). CONCLUSIONS - Differences in care delivery patterns do not yield large differences in glycemic control for patients with type 1 diabetes who were recruited in the U.S. and Canada for a large randomized trial.
引用
收藏
页码:1149 / 1153
页数:5
相关论文
共 30 条
[1]  
[Anonymous], 1995, DIABETES, V44, P968
[2]   Recent findings on preventable hospitalizations [J].
Billings, J ;
Anderson, GM ;
Newman, LS .
HEALTH AFFAIRS, 1996, 15 (03) :239-249
[3]  
DCCT Res Grp, 1986, DIABETES, V35, P530
[4]  
DIABET CONTROL COMPLICATIONS TRIAL RES GRP, 1995, DIABETES CARE, V18, P1468
[5]   All payer, single payer, managed care, no payer: Patients' perspectives in three nations [J].
Donelan, K ;
Blendon, RJ ;
Benson, J ;
Leitman, R ;
Taylor, H .
HEALTH AFFAIRS, 1996, 15 (02) :254-265
[6]   Comparing health care expenditures between systemic lupus erythematosus patients in Stanford and Montreal [J].
Gironimi, G ;
Clarke, AE ;
Hamilton, VH ;
Danoff, DS ;
Bloch, DA ;
Fries, JF ;
Esdaile, JM .
ARTHRITIS AND RHEUMATISM, 1996, 39 (06) :979-987
[7]  
GOEL V, 1996, PATTERNS HLTH CARE O, P5
[8]  
GOLDSTEIN DE, 1987, CLIN CHEM, V33, P2267
[9]   TESTS OF GLYCEMIA IN DIABETES [J].
GOLDSTEIN, DE ;
LITTLE, RR ;
LORENZ, RA ;
MALONE, JI ;
NATHAN, D ;
PETERSON, CM .
DIABETES CARE, 1995, 18 (06) :896-909
[10]   An international comparison of cancer survival: Toronto, Ontario, and Detroit, Michigan, metropolitan areas [J].
Gorey, KM ;
Holowaty, EJ ;
Fehringer, G ;
Laukkanen, E ;
Moskowitz, A ;
Webster, DJ ;
Richter, NL .
AMERICAN JOURNAL OF PUBLIC HEALTH, 1997, 87 (07) :1156-1163